A smart nanocomposite system for controlled insulin release and glucose sensing in diabetes management

IF 5.8 3区材料科学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Nanoscale Pub Date : 2025-06-23 DOI:10.1039/d5nr01437a

Dan Wang, Yaoyao Wang, Wilson Dumisani Gamuchirai Dube, Jiarong Zhang, Jie Gao, Xue Tang, Gisèle Ineza Urujeni, Yajie Zhang, Linjie Zhao, Hua He, Deli Xiao, Pierre Dramou

{"title":"A smart nanocomposite system for controlled insulin release and glucose sensing in diabetes management","authors":"Dan Wang, Yaoyao Wang, Wilson Dumisani Gamuchirai Dube, Jiarong Zhang, Jie Gao, Xue Tang, Gisèle Ineza Urujeni, Yajie Zhang, Linjie Zhao, Hua He, Deli Xiao, Pierre Dramou","doi":"10.1039/d5nr01437a","DOIUrl":null,"url":null,"abstract":"Diabetes is a global health challenge, driving the need for novel solutions in glucose monitoring and insulin delivery. Here, we present a next-generation glucose-responsive nanocomposite, ZIF-8@Ins-GOx/AuNCs, designed for simultaneous controlled insulin release and real-time glucose sensing. This dual-functional system synergistically integrates zeolite imidazolate framework-8 (ZIF-8), glucose oxidase (GOx), and gold nanoclusters (AuNCs), creating a highly efficient platform for personalized diabetes management. The nanocomposite exhibits an impressive glucose detection range (2.50–200 mM) with high sensitivity (LOD = 0.80 mM), offering unprecedented accuracy for early diagnosis and monitoring. In addition, it demonstrates a glucose-triggered insulin release profile with exceptional encapsulation efficiency (90%) and sustained release under hyperglycemic conditions. Comprehensive <em>in vitro</em> studies reveal excellent biocompatibility, with cell viability greater than 80% at concentrations up to 22.2 mM, highlighting the safety for potential clinical use. This work represents a significant leap forward in the development of adaptive drug delivery systems, offering a versatile, scalable platform with the potential to revolutionize not only diabetes treatment but also broader biomedical applications demanding precise, self-regulated therapeutic interventions.","PeriodicalId":92,"journal":{"name":"Nanoscale","volume":"269 1","pages":""},"PeriodicalIF":5.8000,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanoscale","FirstCategoryId":"88","ListUrlMain":"https://doi.org/10.1039/d5nr01437a","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Diabetes is a global health challenge, driving the need for novel solutions in glucose monitoring and insulin delivery. Here, we present a next-generation glucose-responsive nanocomposite, ZIF-8@Ins-GOx/AuNCs, designed for simultaneous controlled insulin release and real-time glucose sensing. This dual-functional system synergistically integrates zeolite imidazolate framework-8 (ZIF-8), glucose oxidase (GOx), and gold nanoclusters (AuNCs), creating a highly efficient platform for personalized diabetes management. The nanocomposite exhibits an impressive glucose detection range (2.50–200 mM) with high sensitivity (LOD = 0.80 mM), offering unprecedented accuracy for early diagnosis and monitoring. In addition, it demonstrates a glucose-triggered insulin release profile with exceptional encapsulation efficiency (90%) and sustained release under hyperglycemic conditions. Comprehensive in vitro studies reveal excellent biocompatibility, with cell viability greater than 80% at concentrations up to 22.2 mM, highlighting the safety for potential clinical use. This work represents a significant leap forward in the development of adaptive drug delivery systems, offering a versatile, scalable platform with the potential to revolutionize not only diabetes treatment but also broader biomedical applications demanding precise, self-regulated therapeutic interventions.

Abstract Image

查看原文本刊更多论文

一种在糖尿病管理中控制胰岛素释放和葡萄糖传感的智能纳米复合系统

糖尿病是一项全球性的健康挑战，推动了对血糖监测和胰岛素输送新解决方案的需求。在这里，我们提出了下一代葡萄糖反应纳米复合材料ZIF-8@Ins-GOx/AuNCs，设计用于同时控制胰岛素释放和实时葡萄糖传感。这种双功能系统协同整合了咪唑酸分子筛框架-8 （ZIF-8）、葡萄糖氧化酶（GOx）和金纳米团簇（aunc），为个性化糖尿病管理创造了一个高效的平台。该纳米复合材料具有令人印象深刻的葡萄糖检测范围（2.50-200 mM）和高灵敏度（LOD = 0.80 mM），为早期诊断和监测提供了前所未有的准确性。此外，它还具有葡萄糖触发的胰岛素释放特性，具有卓越的包封效率（90%）和高血糖条件下的持续释放。全面的体外研究显示出良好的生物相容性，在22.2 mM浓度下细胞存活率大于80%，强调了潜在临床应用的安全性。这项工作代表了自适应给药系统发展的重大飞跃，提供了一个多功能的、可扩展的平台，不仅有可能彻底改变糖尿病治疗，而且有可能改变更广泛的生物医学应用，需要精确的、自我调节的治疗干预。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nanoscale CHEMISTRY, MULTIDISCIPLINARY-NANOSCIENCE & NANOTECHNOLOGY

CiteScore

12.10

自引率

3.00%

发文量

1628

审稿时长

1.6 months

期刊介绍： Nanoscale is a high-impact international journal, publishing high-quality research across nanoscience and nanotechnology. Nanoscale publishes a full mix of research articles on experimental and theoretical work, including reviews, communications, and full papers.Highly interdisciplinary, this journal appeals to scientists, researchers and professionals interested in nanoscience and nanotechnology, quantum materials and quantum technology, including the areas of physics, chemistry, biology, medicine, materials, energy/environment, information technology, detection science, healthcare and drug discovery, and electronics.